TCS Cream

DRUG2 trials

Sponsors

Hoffmann-La Roche, Cara Therapeutics, Inc.

Conditions

Atopic DermatitisPruritus

Phase 2

A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis

CompletedNCT02340234

Hoffmann-La RocheAtopic Dermatitis

Start: 2015-05-31End: 2016-04-30Updated: 2017-10-02

Phase 3

Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis

TerminatedNCT05387707

Cara Therapeutics, Inc.Atopic Dermatitis, Pruritus

Start: 2022-08-16End: 2024-02-02Updated: 2024-02-22

Related Papers

Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: An Integrated Analysis of Eight Clinical Trials

American Journal of Clinical Dermatology2023-05-1760 citations